stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) Net income
Arcutis Biotherapeutics, Inc.'s net income for fiscal 2025 was −$16.1M, compared with −$140.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $29.9M. Over the past ten years it has ranged from −$311.5M (fiscal 2022) to −$5.0M (fiscal 2017); the current reading is higher than 89% of that period. Net income has risen for 3 consecutive fiscal years. Arcutis Biotherapeutics, Inc. ranks 45th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$16.1M | — |
| FY2024 | −$140.0M | — |
| FY2023 | −$262.1M | — |
| FY2022 | −$311.5M | — |
| FY2021 | −$206.4M | — |
| FY2020 | −$135.7M | — |
| FY2019 | −$42.0M | — |
| FY2018 | −$19.3M | — |
| FY2017 | −$5.0M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $8.8M | (41.36%) |
| Jun 2026 | $15.0M | — |
| Mar 2026 | −$11.3M | — |
| Dec 2025 | $17.4M | 134.75% |
| 29 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. | $29.9M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$56.2M |
| TNGX Tango Therapeutics, Inc. compare | −$123.7M |
| ABCL AbCellera Biologics Inc. compare | −$164.7M |
| EWTX Edgewise Therapeutics, Inc. compare | −$197.2M |
| DNTH Dianthus Therapeutics, Inc. compare | −$202.1M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$220.5M |
| RLAY Relay Therapeutics, Inc. compare | −$286.0M |
| DFTX Definium Therapeutics, Inc. compare | −$353.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ARQT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement